Latest news with #GLP-1R
Yahoo
4 hours ago
- Business
- Yahoo
Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs
Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. The research collaboration and exclusive worldwide license agreement will see Deep Apple tasked with discovering and optimising drug candidates directed at a non-incretin G protein-coupled receptor target. Novo Nordisk will then have the option to develop, manufacture, and commercialise the resulting compounds and products in all indications. Duties will be transferred before the start of clinical trials, though both companies will collaborate on the research plan. The breakdown of the $812m figure was not disclosed, though it is constituted of an upfront payment, research costs, and milestone payments. Deep Apple is also in line to receive royalties on sales on any products borne from the partnership that reach market. The agreement marks a significant moment for Novo Nordisk, as it channels substantial resources into research that is not centred around incretins. The drugmaker's flagship drug semaglutide, known under the brand names Wegovy and Ozempic for obesity and type 2 diabetes treatment respectively, targets the glucagon-like peptide-1 receptor (GLP-1R), a key component of the incretin system. Eli Lilly's rival drug tirzepatide, known under the brand names Mounjaro and Zepbound for weight loss and type 2 diabetes respectively, is a dual incretin – targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. Novo Nordisk and Deep Apple have not disclosed the name of their intended target, saying only that is a 'non-incretin G-protein coupled receptor (GPCR) that is well-suited for Deep Apple's platform.' Deep Apple's drug discovery platform combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM). 'Novo Nordisk is developing a range of potential oral medicines for cardiometabolic diseases across modalities and targets, as we know that people living with these diseases have different needs and preferences,' said Jacob Sten Petersen, senior vice president of diabetes, obesity and MASH therapeutic area at Novo Nordisk. 'We look forward to exploring this novel target further based on Deep Apple's AI-powered platform and expertise in small molecule drug discovery,' Petersen added. Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding. The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Deep Apple is the latest biotech Novo Nordisk has tapped in efforts to regain market share in the cardiometabolic disease market. Eli Lilly's tirzepatide is outpacing semaglutide in terms of sales, leading to declining share prices for the Danish big pharma. Novo Nordisk's new candidate, CagriSema, was hyped as a successor to semaglutide only to produce underwhelming results in a Phase III trial. Incidentally, the company listed two new trials on this week as it continues to evaluate the efficacy of the drug. Struggles at the drugmaker culminated in long-time CEO Lars Fruergaard Jørgensen stepping down in May 2025. Other deals initiated by Novo Nordisk in 2025 include a $345m pact with Gensaic, $50m invested in Variant Bio, and a potential $2bn deal with United Laboratories for a GLP-1/GIP/glucagon triple receptor agonist. "Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
Vantive to invest $1bn for kidney care advancement
Vantive is investing $1bn towards advancing its kidney care and vital organ support proposition. The company, which was formerly Baxter's kidney care unit, becoming Vantive after being spun out as part of a $3.5bn divestment deal with global investment firm Carlyle in 2024, stated that the investment would be allocated over a five-year period and have a particular focus on advancing R&D and manufacturing capacity. According to Vantive, hastening the course of innovation is critical in order to meet the demand presented by the increasing burden of chronic kidney disease (CKD) end-stage renal disease (ESRD) – which research indicates places an annual healthcare burden on Europe of around $140bn annually. In addition, there is a pressing need for acute organ support therapy options, with research indicating that 60% of patients in the intensive care unit (ICU) may have acute kidney injury. Through the development of digitally enabled dialysis and critical care products and services, the company said it aims to power earlier and better-informed clinical decision-making, minimise disruption of care for patients and clinical teams, shift kidney care management from episodic to proactive, and enhance patient-care team connectivity. In turn, Vantive also plans to build a 'stronger' foundation for digital support, with plans to develop existing products including its virtual reality (VR) training on-demand for clinicians using Vantive's therapies, and its remote patient management platform. Ahead of the European Renal Association (ERA) conference where further details are set to be announced, Vantive CEO Chris Toth said the funding underscored its commitment to 'shaping the future of kidney care and vital organ support'. 'Better outcomes are possible when care is more accessible, more intuitive, and more connected to the needs of patients as well as the realities of the modern healthcare ecosystem. 'That's why we are focused on transforming where and how therapy is delivered – from life-saving critical care for patients in a hospital, to life-sustaining dialysis for patients at home.' CKD is a metabolic disorder related to conditions such as diabetes, for Glucagon-like peptide-1 receptor agonists (GLP-1Rs) have shown promise. Due to their potentially wider therapeutic benefits, GLP-1R could potentially transform treatment paradigms of multiple chronic diseases, as per GlobalData analysis. "Vantive to invest $1bn for kidney care advancement " was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
Novo Nordisk and Eli Lilly Lead, but New Entrants Eye GLP-1RA Market Opportunities
Explore the GLP-1R agonists market, uncovering new opportunities for repurposing beyond type 2 diabetes and obesity. Discover insights on unmet needs, pipeline analysis, and competitive landscapes, highlighting major players like Novo Nordisk and Eli Lilly and potential new entrants. Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "GLP-1R Agonists - Label Extensions/Drug Repurposing: Market Overview" report has been added to report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory are being investigated in different diseases in the metabolic, neurologic, and cardiologic Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new Scope Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation. Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing. Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas. Overview of current major players in the GLP-1RAs space and potential future players. GLP-1RAs global market outlook and deals overview. Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future. Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface 2 Executive Summary3 GLP-1R Agonists Overview3.1 What Are GLP-1R Agonists3.2 GLP-1R in the Body3.3 History of GLP-1R Agonists4 Industry Trends4.1 Oral GLP-1Ras4.2 Lower Dosing Frequency4.3 Combination and Dual/Triple Agonists4.4 Repurposing GLP-1Ras5 Marketed Products5.1 Global GLP-1RA Marketed Landscape5.2 Marketed GLP-1Ras5.3 Challenges and Opportunities in GLP-1RA Repurposing5.4 Key Opinion Leader Perspectives on GLP-1RA Unmet Needs6 Pricing and Reimbursement Assessment Case Study: Ozempic7 Pipeline Analysis7.1 Top 20 Indications with GLP-1RAs in Development7.2 Top Five Therapeutic Areas with the Most GLP-1RA Pipeline Assets7.3 GLP-1RA Pipeline Candidates7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney Disease Treatment Landscape?7.5 Where Are GLP-1RAs Expected to Position in the Future Heart Failure Treatment Landscape?7.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment for Heart Failure and Chronic Kidney Disease7.7 GLP-1RA Opportunities Beyond Planned Label Expansions7.8 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Polycystic Ovary Syndrome8 Opportunities and Challenges8.1 Opportunities: the Role of GLP-1RAs in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis8.2 Opportunities: GLP-1RAs in Liver Diseases8.3 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Liver Diseases8.4 Opportunities: the Role of GLP-1RAs in Neurodegenerative Diseases8.5 Opportunities: GLP-1RAs in Central Nervous System Disorders8.6 Key Opinion Leader Perspectives on GLP-1RAs in the Treatment of Parkinson's Disease8.7 Opportunities: the Role of GLP-1RAs in Diastolic Heart Failure and Stroke8.8 Opportunities: GLP-1RAs in Cardiovascular Diseases8.9 Opportunities: the Role of GLP-1RAs in Chronic Kidney Disease8.10 Opportunities: GLP-1RAs in Other Diseases9 Companies9.1 Current Major Player: Novo Nordisk9.2 Current Major Player: Eli Lilly9.3 Potential Future Players9.4 Key Opinion Leader Perspectives on Future Players in the GLP-1RA Space10 Market Outlook and Deals10.1 GLP-1RA Global Market10.2 Top 20 Major Deals and Acquisitions Between 2022 and 2025 with GLP-1RasCompany Coverage Includes: Novo Nordisk AS Eli Lilly and Co Shanghai Minwei Biotechnology Co Ltd Metsera Inc Sihuan Pharmaceutical Holdings Group Ltd Hanmi Pharmaceuticals Co Ltd Jiangsu Hengrui Medicine Co Ltd AstraZeneca Plc PegBio Co Ltd Beijing QL Biopharmaceutical Co Ltd Sciwind Biosciences Co Ltd U.S. National Institutes of Health Boehringer Ingelheim International GmbH i2O Therapeutics Inc Zhejiang Doer Biologics Corp CSPC Pharmaceutical Group Ltd Peptron Inc Carmot Therapeutics Inc Amogen Pharma Pvt Ltd BioLingus AG The United Laboratories International Holdings Ltd Tonghua Dongbao Pharmaceutical Co Ltd Annovis Bio Inc ImmunoForge Co Ltd Biogenomics Ltd China Pharmaceutical University Zhejiang Heze Pharmaceutical Technology Co Ltd Zhuhai United Laboratories Co Ltd Hangzhou Jiuyuan Gene Engineering Co Ltd Structure Therapeutics Inc Altimmune Inc Chia Tai Tianqing Pharmaceutical Group Co Ltd Gmax Biopharm LLC Guangzhou Dazhou Biomedical Technology Co Ltd Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd Huadong Medicine Co Ltd Innovent Biologics Inc Merck & Co Inc Neuraly Inc Onegene Biotechnology Inc Protheragen Inc RenaissThera Pvt Ltd Sekkei Inc Uni-Bio Science Group Ltd HEC Pharma Co Ltd Jiangsu Hansoh Pharmaceutical Group Co Ltd Cascade Pharmaceuticals Inc D&D Pharmatech Co Ltd Huons Global Co Ltd Immunwork Inc Leto Laboratories Co Ltd MetaVia Inc Pfizer Inc Qilu Regor Therapeutics Inc Sanofi Xintrum Pharmaceuticals Ltd Gan & Lee Pharmaceuticals Co Ltd Adocia SAS AnyGen Co Ltd Ascendis Pharma AS AULBIO Co Ltd BrightGene Bio-Medical Technology Co Ltd Camurus AB HK inno.N Corp Hybio Pharmaceutical Co Ltd IGC Pharma Inc Lancaster University Laxxon Medical GmbH Poolbeg Pharma Plc ProGen Co Ltd Septerna Inc Shanghai Innogen Pharmaceutical Technology Co Ltd Shenzhen Salubris Pharmaceuticals Co Ltd Sun Pharmaceutical Industries Ltd Suzhou Wingtech Pharmaceutical Technology Co Ltd Theertha Biopharma Pvt Ltd Verdiva Bio Ltd Vivani Medical Inc Yunovia Co Ltd Adare Pharma Solutions Amgen Inc Apeloa Pharmaceutical Co Ltd ApicHope Pharmaceutical Co Ltd Arecor Therapeutics Plc Biolexis Therapeutics Inc Biomea Fusion Inc Biomed Industries Inc BioNxt Solutions Inc California Institute for Biomedical Research China Medical System Holdings Ltd Chongqing Chenan BioPharm Co Ltd CinFina Pharma LLC Crinetics Pharmaceuticals Inc CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd Daewoong Therapeutics Inc Diabetology (Products) Ltd Dx&Vx Efil Bioscience Inc Entera Bio Ltd Gilead Sciences Inc Guangzhou BeBetter Medicine Technology Co Ltd HangZhou HuiSheng Biotech Pharmaceutical Co Ltd Hepagene Therapeutics Inc HighField Biopharmaceuticals, Inc. Hua Medicine Shanghai Ltd INVENT Pharmaceuticals Inc Inventage Lab Inc iX Biopharma Ltd Jiangsu Normal University Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd Livzon Pharmaceutical Group Inc MeiraGTx Holdings Plc MindRank Ltd Niedlfree Technologies Pvt Ltd OPKO Health Inc Remedium Bio Inc Scohia Pharma Inc Shandong New Era Pharmaceutical Co Ltd SN BioScience Co Ltd Tharimmune Inc Viking Therapeutics Inc vTv Therapeutics Inc Youngene Therapeutics Co Ltd Zealand Pharma AS 4Moving Biotech Abaxys Therapeutics SA Aerami Therapeutics Holdings Inc AI Proteins Inc Akrikhin Alphamab Oncology Aprilbio Co Ltd Ascletis Pharma Inc Beijing Eastern Biotech Co Ltd Beijing SL Pharmaceutical Co Ltd Biora Therapeutics Inc Bostal Drug Delivery Co Ltd Bristol-Myers Squibb Co Chengdu Brilliant Pharmaceutical Co Ltd China Resources Double-Crane Pharmaceutical Co Ltd Closed Loop Medicine Ltd Coya Therapeutics Inc Delpor Inc Duke University Enteris BioPharma Inc G2GBIO Inc GlyTech Inc Gubra ApS Halo Therapeutics Ltd HEC Pharm Group Hualan Biological Engineering Inc Iconovo AB Icure Pharmaceutical Inc Imagine Pharma LLC Immupharma Plc Imperial College London Innopharmax Inc Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd Kailera Therapeutics Inc Kariya Pharmaceuticals IVS Kunming Yinnuo Medical Technology Co. Ltd. Lanzhou Institute of Biological Products Co Ltd Lepu Medical Technology (Beijing) Co Ltd Mapi Pharma Ltd MBX Biosciences Inc Metaphore Biotechnologies Inc Nanexa AB National Institute of Biomedical Imaging and Bioengineering NutriBand Inc Oramed Pharmaceuticals Inc Original BioMedicals Co Ltd Pep2Tango Therapeutics Inc ProLynx LLC Qilu Pharmaceutical Co Ltd QuiaPEG Pharmaceuticals AB Rani Therapeutics LLC Rivus Pharmaceuticals Inc Rose Pharma Inc R-Pharm Sail Biomedicines Inc Shandong Boan Biotechnology Co Ltd Shanghai Fosun Pharmaceutical (Group) Co Ltd Sino Biopharmaceutical Ltd Syracuse University Terns Pharmaceuticals Inc Terry Suzhou Pharmaceutical Co Ltd The University of Adelaide Twist Bioscience Corp University of Padova University of Ulster Vanderbilt University Virtici LLC Wuxi Hebang Biotechnology Co Ltd Yichang Humanwell Pharmaceutical Co Ltd Yonsei University College of Medicine Zhejiang HuaYang Pharmaceutical Co Ltd Zhongshan Wanhan Pharmaceutical Co Ltd For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025
Skye Bioscience, Inc. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, May 8th at 1:30 p.m. PT/4:30 p.m. ET to discuss its 2025 first quarter financial results. An earnings press release will be issued after the market close on May 8th. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay and transcript will be available at the same website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090 ) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: . Connect with us on X and LinkedIn . CONTACTS Investor Relations ir@ (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@ (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ (628) 234-3889
Yahoo
14-04-2025
- Business
- Yahoo
Skye Bioscience to Conduct Meetings at Piper Sandler Conference
SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relationsir@ 410-0266 LifeSci Advisors, Mike Moyermmoyer@ 308-4306 Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@ 234-3889 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking in to access your portfolio
